Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Inclusion Criteria:

Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet all of the following criterion:

Coverage of the body surface area (BSA) of 10% or more with plaques
A score of 3 or more on the IGA (Investigator Global Assessment) scale

A PASI score of at least 12 at baseline;

Exclusion Criteria:

Have forms of psoriasis other than the required "plaque psoriasis"
Women of childbearing potential
Recent use of investigational drugs or treatment with other biological therapies (wash-out periods required)
Previous treatment with this investigational drug
Subjects with active or history of clinically significant cardiac, kidney or liver abnormalities

Other protocol-defined inclusion/exclusion criteria may have applied.